Herpes zoster-associated mortality in Europe: A systematic review

BMC Public Health

Volumn 15, Issue 1, 2015, Pages

  Bricout, Hélène ^a   Haugh, Margaret ^b   Olatunde, Olugbenga ^c   Gil Prieto, Ruth ^d  

^a SANOFI PASTEUR   (France)

^b MediCom Consult   (France)

^c OFFICE FOR NATIONAL STATISTICS   (United Kingdom)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Europe; Herpes zoster; Mortality; Varicella zoster virus

Indexed keywords

VARICELLA ZOSTER VACCINE;

AGED; BELGIUM; EPIDEMIOLOGY; EUROPE; FEMALE; FRANCE; GERMANY; HEALTH STATUS; HERPES ZOSTER; HISTORY; HUMAN; INCIDENCE; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; PORTUGAL; POSTHERPETIC NEURALGIA; REGISTER; SPAIN; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM; VARICELLA ZOSTER VIRUS;

AGED; BELGIUM; ENGLAND; EUROPE; FEMALE; FRANCE; GERMANY; HEALTH STATUS; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HISTORY, 18TH CENTURY; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; NEURALGIA, POSTHERPETIC; PORTUGAL; REGISTRIES; SPAIN;

EID: 84938988213     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/s12889-015-1753-y     Document Type: Review

References (48)

1. Guidelines for the management of shingles. report of a working group of the British Society for the Study of Infection (BSSI). J Infect. 1995;30:193-200.
2. Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine. 2001;19:3076-90.
3. Gross G, Schofer H, Wassilew S, Friese K, Timm A, Guthoff R, et al. Herpes zoster guideline of the German Dermatology Society (DDG). J Clin Virol. 2003;26:277-89. discussion 291-273.
4. Lee VK, Simpkins L. Herpes zoster and postherpetic neuralgia in the elderly. Geriatr Nurs. 2000;21:132-5. quiz 136.
5. Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV, et al. The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr. 2002;161:588-93.
6. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32:1481-6.
7. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341-9.
8. Sengupta N, Breuer J. A global prospective of the epidemiology and burden of varicella-zoster-virus. Curr Ped Rev. 2009;5:207-28.
9. Hannouche D, Alfandari S, Bouhour D, Fouchard N, Geffray L, Quinet B. Management of VZV infections [Prise en charge des infections à VZV]. Med Mal Infect. 1998;28:1.
10. Johnson RW, Wasner G, Saddier P, Baron R. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother. 2007;7:1581-95.
11. Scott FT, Johnson RW, Leedham-Green M, Davies E, Edmunds WJ, Breuer J. The burden of Herpes Zoster: a prospective population based study. Vaccine. 2006;24:1308-14.
12. Scott FT, Leedham-Green ME, Barrett-Muir WY, Hawrami K, Gallagher WJ, Johnson R, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol. 2003;70 Suppl 1:S24-30.
13. Pinchinat S, Cebrian-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13:170.
14. Mick G, Hans G. Postherpetic neuralgia in Europe: the scale of the problem and outlook for the future. J Clin Gerontol Geriatr. 2013;4:102-8.
15. European Detailed Mortality Database. [ http://data.euro.who.int/dmdb/ ]
16. French Mortality Database: CepiDc. [ http://www.cepidc.inserm.fr/site4/ ]
17. Office for National Statistics (England and Wales). [ http://www.statistics.gov.uk ]
18. German Federal Health Monitoring System. [ http://www.gbe-bund.de/gbe10/pkg-navigation.prc-sitemap?p-uid=gast&p-aid=&p-sprache=E&p-help-context=H-HOME ]
19. PRISMA Statement website. [ http://www.prisma-statement.org/ ].
20. Eurostat. [ http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tps00001&plugin=1
21. Bilcke J, Marais C, Ogunjimi B, Willem L, Hens N, Beutels P. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30:675-84.
22. Brisson M, Edmunds WJ. Epidemiology of Varicella-Zoster Virus in England and Wales. J Med Virol. 2003;70 Suppl 1:S9-14.
23. de Melker H, Berbers G, Hahne S, Rumke H, van den Hof S, de Wit A, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine. 2006;24:3946-52.
24. Gil A, Gil R, Alvaro A, San Martin M, Gonzalez A. Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004). BMC Infect Dis. 2009;9:55.
25. Gil-Prieto R. The Burden of Hospitalisations for Herpes Zoster Ophtalmicus in Spain (1997-2008). World J Vaccines. 2012;02:164-71.
26. Gil-Prieto R, San Martin M, Alvaro-Meca A, Gonzalez-Lopez A, Gil de Miguel A. Herpes zoster hospitalizations of patients with chronic illnesses in Spain, 198-2004. Vacunas. 2011;12:95-101.
27. Gonzalez Chiappe S, Sarazin M, Turbelin C, Lasserre A, Pelat C, Bonmarin I, et al. Herpes zoster: burden of disease in France. Vaccine. 2010;28:7933-8.
28. Mesquita M, Froes F. Hospital admissions for herpes zoster in portugal between 2000 and 2010. Acta Med Port. 2013;26:531-6.
29. Perez-Sola MJ, Torre-Cisneros J, Perez-Zafrilla B, Carmona L, Descalzo MA, Gomez-Reino JJ. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. Med Clin (Barc). 2011;137:533-40.
30. Ultsch B, Siedler A, Rieck T, Reinhold T, Krause G, Wichmann O. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
31. van Lier A, van der Maas NA, Rodenburg GD, Sanders EA, de Melker HE. Hospitalization due to varicella in the Netherlands. BMC Infect Dis. 2011;11:85.
32. Varicella and herpes zoster surveillance and vaccination recommendations 2010-2011 [ http://venice.cineca.org/report-final-varicella.pdf ]
33. Mahamud A, Marin M, Nickell SP, Shoemaker T, Zhang JX, Bialek SR. Herpes zoster-related deaths in the United States: validity of death certificates and mortality rates, 1979-2007. Clin Infect Dis. 2012;55:960-6.
34. Lin F, Hadler JL. Epidemiology of primary varicella and herpes zoster hospitalizations: the pre-varicella vaccine era. J Infect Dis. 2000;181:1897-905.
35. Chant KG, Sullivan EA, Burgess MA, Ferson MJ, Forrest JM, Baird LM, et al. Varicella-zoster virus infection in Australia. Aust N Z J Public Health. 1998;22:413-8.
36. MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect. 2003;131:675-82.
37. DeLaGarza VW, Arbogast JG, Podolinski CF, Gunel E. Reactivation of herpes zoster (shingles) infection associated with an increased risk of death in immunocompetent older persons. W V Med J. 2008;104:22-4.
38. Sogaard OS, Lohse N, Ostergaard L, Kronborg G, Roge B, Gerstoft J, et al. Morbidity and risk of subsequent diagnosis of HIV: a population based case control study identifying indicator diseases for HIV infection. PLoS One. 2012;7:e32538.
39. Breuer J, Pacou M, Gauthier A, Brown MM. Herpes zoster as a risk factor for stroke and TIA: a retrospective cohort study in the UK. Neurology. 2014;82:206-12.
40. Sreenivasan N, Basit S, Wohlfahrt J, Pasternak B, Munch TN, Nielsen LP, et al. The short- and long-term risk of stroke after herpes zoster - a nationwide population-based cohort study. PLoS One. 2013;8:e69156.
41. de Saint-Hubert M, Schoevaerdts D, Poulain G, Cornette P, Swine C. Risk factors predicting later functional decline in older hospitalized patients. Acta Clin Belg. 2009;64:187-94.
42. Hoogerduijn JG, Schuurmans MJ, Duijnstee MS, de Rooij SE, Grypdonck MF. A systematic review of predictors and screening instruments to identify older hospitalized patients at risk for functional decline. J Clin Nurs. 2007;16:46-57.
43. Vidan Astiz MT, Sanchez Garcia E, Alonso Armesto M, Montero Errasquin B, Martinez de la Casa A, Ortiz FJ, et al. Functional decline during hospitalization in elderly patients. Benefits of admission to the geriatrics service. Rev Esp Geriatr Gerontol. 2008;43:133-8.
44. Agarwal R, Norton JM, Konty K, Zimmerman R, Glover M, Lekiachvili A, et al. Overreporting of deaths from coronary heart disease in New York City hospitals, 2003. Prev Chronic Dis. 2010;7:A47.
45. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation. 2004;110:522-7.
46. Hunt Jr LW, Silverstein MD, Reed CE, O'Connell EJ, O'Fallon WM, Yunginger JW. Accuracy of the death certificate in a population-based study of asthmatic patients. JAMA. 1993;269:1947-52.
47. Bancroft EA, Lee S. Use of electronic death certificates for influenza death surveillance. Emerg Infect Dis. 2014;20:78-82.
48. European Parliament. Commission Regulation (EU) No 328/2011 of 5 April 2011. OJ. 2011;L90:22-4.